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Slow-Cycling Therapy-Resistant Cancer Cells
Nathan Moore,1 JeanMarie Houghton,1,2 and Stephen Lyle1,3
Tumor recurrence after chemotherapy is a major cause of patient morbidity and mortality. Recurrences are
thought to be secondary to small subsets of cancer cells that are better able to survive traditional forms of
chemotherapy and thus drive tumor regrowth. The ability to isolate and better characterize these therapy-
resistant cells is critical for the future development of targeted therapies aimed at achieving more robust and
long-lasting responses. Using a novel application for the proliferation marker carboxyfluorescein diacetate,
succinimidyl ester (CFSE), we have identified a population of slow-cycling, label-retaining tumor cells in both in
vitro sphere cultures and in vivo xenograft models. Strikingly, label-retaining cells exhibit a multifold increase in
ability to survive traditional forms of chemotherapy and reenter the cell cycle. Further, we demonstrate the
innovative application of CFSE to live sort slow-cycling tumor cells and validate their chemoresistance and
tumorigenic potential.
Introduction
The incidence of recurrence after treatment in patientswith epithelial tumors is a major obstacle in developing
truly curative treatments. Although many stage II colon
cancer patients show initial responses to standard che-
motherapies, 5-year recurrence rates can be as high as 25% [1].
In breast cancer patients, 15-year recurrence rates are as high
as 20% [2]. While factors associated with recurrence (sizes,
grade, etc.) can suggest which tumors are likely to recur, the
inability to accurately predict recurrence risk can lead to both
unnecessary and insufficient treatment. It appears likely that
subsets of tumor cells evade initial chemotherapy and survive
to repropagate the tumor [3,4]. Traditional chemotherapies
like 5-fluorouracil (5-FU) and Oxaliplatin require active cy-
cling cells to trigger cell death [4,5]. Cells that are quiescent or
cycling slowly are therefore less likely to be susceptible to
these drugs, suggesting an inherent recurrence mechanism in
which slow-cycling cells evade therapeutic agents and re-
propagate tumors. Evidence for such chemoresistance abili-
ties are observed in normal skin tissue where more slowly
dividing cells in the bulge survive chemotherapy to regener-
ate the hair follicle [6]. In the mouse forebrain, high doses of
tritiated thymidine (3H-TdR) kill constitutively proliferating
cells, but have no effect on quiescent cells [7].
Similar to adult tissues, slow-cycling populations of cells
have been identified in cancer tissues. Roesch et al. demon-
strated that primary melanoma cell lines contain a PKH26
label–retaining population that has a doubling time of 4
weeks [8]. Using the same PKH dye, Kusumbe and Bapat
demonstrated the existence of a slow-cycling population of
cells in ovarian cancer [9]. Dembinski and Krauss used Vy-
brant DiI to demonstrate a pancreatic adenocarcinoma
slow-cycling cell population [10]. Even cell lines grown for
years in vitro, like MDA.MB.231, have been found to contain
label-retaining cell (LRC) populations [11]. The contribution
that slow-cycling populations play in chemotherapy resis-
tance is not well studied and it is unclear whether this
characteristic may be a significant factor in tumor recurrence.
In this study, we use an innovative application for the cell
tracing dye carboxyfluorescein diacetate, succinimidyl ester
(CFSE) to identify and isolate slow-cycling LRCs in both
commonly used colon and breast tumor cell lines, as well as
a primary human breast tumor. We demonstrate that these
slow-cycling cells are tumorigenic and more resistant to
traditional chemotherapies than rapidly dividing cells. Im-
portantly, slow-cycling cells survive treatment and demon-
strate active DNA synthesis after the removal of
chemotherapy drugs, suggesting that they may drive recur-
rence in the clinical setting.
Materials and Methods
Cell lines and CFSE labeling
Adherent HCT116 (ATCC CCL-247) and MDA-MB-231
(ATCC HTB-26) cultures were grown in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco 11995) or Roswell Park
Memorial Institute (RPMI) medium (Gibco 22400), respec-
tively, with 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin.
Sphere cultures were grown in Sphere media consisting of
DMEM/F12 (Gibco 11320) with 1· B-27 (Gibco 12587),
15mM HEPES (Gibco 15630), 1% penicillin/streptomycin,
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20 ng/mL basic fibroblast growth factor (Invitrogen 13256-
029), and 10 ng/mL epithelial growth factor (EGF) (Sigma
E9644). Spheres were digested in alkaline solution (Sphere
media with NaOH, pH 11.6) and quenched with acidic so-
lution (Sphere media with HCl, pH 1.7) then filtered through
a 40 mM mesh.
CFSE labeling was conducted with 10 mM CFSE stock ac-
cording to manufacturer’s protocol for cells in suspension
(Molecular Probes C34554).
Mice and tumor xenografts
NOD.CB17-Prkdc scid/J mice were purchased from Jack-
son Laboratories and housed in the UMass Animal Medicine
Facilities.
Adherent HCT116 (1 · 107) or MDA-MB-231 (7 · 106)
CFSE-labeled cells were suspended in Matrigel (BD Bios-
ciences 354234) and injected subcutaneously into the flank or
#3 mammary fat pad, respectively. After 2 weeks, two to four
tumor digests were combined to obtain adequate cell num-
bers and live sorted.
Primary patient breast tumor tissue (designated 2597T)
was obtained from the UMass Cancer Center Tissue and
Tumor Bank with IRB approval and was exclusively pas-
saged in NOD/SCID mice.
Tumor digests weremechanically and enzymatically (2mg/
mL collagenase) digested, dissociated on a gentleMACs Dis-
sociator (Miltenyi Biotech), and filtered through a 40mMmesh.
To determine CFSE + cell growth potential, 1.0 · 104
HCT116 or 2.5 · 104 2597T live sorted CFSE + were re-
suspended in Matrigel and regrafted either into flanks or
mammary fat pads.
Chemotherapy enrichment assays
Cells were cultured in Sphere media for at least 1 week
and passaged once before use. Single-cell suspensions of
CFSE-labeled HCT116 cells were plated at 2.0 · 104 cells/mL.
One-week-chased single-cell suspensions were replated at
2.0 · 104 cells/mL in Sphere media containing dimethyl
sulfoxide (DMSO) vehicle control, 2 mM Oxaliplatin (Sigma
9512), 250 mM 5-FU (Sigma F6627), or FOX (Oxaliplatin and
5-FU) for 3 days before being analyzed for CFSE content.
Alternatively, FOX-treated cultures were replated in fresh
Sphere media containing 10 mM BrdU (BD Pharmingen
550891) for 3 days. A range of drug concentrations was ini-
tially used to determine the above concentrations that would
give 75%–90% kill curves.
Mice were injected with 5 · 106 HCT116 CFSE-labeled cells
into the #3 and #8 mammary fat pads. Twelve days after
engraftment (day 0) mice were injected IP with 40mg/kg
5-FU and 10mg/kg Oxaliplatin diluted in phosphate-buffered
saline (PBS). Injections were repeated on days 4 and 8. On
day 12, tumors were collected and processed as described.
BrdU pulsed tumors received 1mg BrdU by IP injection on
days 14, 15, and 16, and were processed on day 17.
Flow cytometry
Single-cell suspensions derived from sphere cultures were
washed in PBS + (PBS with 1% 1M HEPES and 2% FBS).
Single-cell in vivo tumor digests were washed in PBS + and
stained with the epithelial-positive selection marker EpCAM
(eBiosciences 50-9326) and the negative selection markers
TER119, CD31, and CD45 (BD Pharmingen 553673, 553373,
and 553089). In vitro and in vivo samples were suspended in
PBS and 20% Sphere media with 7AAD (BD Pharmingen
559925). A maximum of 5% of the greatest CFSE intense-
Live/Lineage negative cells were collected.
Chemotherapy-treated samples and BrdU-treated samples
were labeled with the viability discriminator Live/Dead Blue
(Invitrogen L23105) and fixed in Cytofix buffer (BD Bios-
ciences 51-2090KZ). BrdU-treated samples were stained with
anti-BrdU antibody (Roche 11170376001, APC secondary
Santa Cruz sc-3818). Final samples were suspended in FACS
buffer (1 · PBS, 1mM sodium azide, and 0.05 g/mL bovine
serum albumin).
Cell cycle analysis was performed on cytofixed cells
in 4¢,6-diamidine-2¢-phenylindole dihydrochloride (DAPI)
(Roche 236276).
All samples were analyzed and sorted by the UMass Med-
ical School Flow Cytometry Facility. The proliferation wizard
from the Modfit analysis package was used to generate gen-
eration peaks from HCT116 in vivo xenografts at 2 weeks.
Staining
Tumor samples were frozen in OCT compound, sectioned
at 6mm thickness, fixed in 4% paraformaldehyde, and stained
with hematoxylin and eosin stains. Fluorescent stains were
mounted with Vectashield containing DAPI (Vector H-1200).
Statistics
Statistical analysis and P values were calculated using the
t-test functions of the GraphPad Prism software.
Results
Detection of in vitro and in vivo LRCs
Sphere cultures are considered to better represent prop-
erties of tumor cells; we, therefore, used this system to de-
termine whether slow-cycling cells were present in the colon
tumor line HCT116. Similar to other groups, we found that in
sphere media, MDA-MB-231 (MDA231) cells formed poorly
proliferative, loosely associated clumps of cells that made
pulse/chase growth assays impractical [12]. Therefore,
MDA231 cells were grown as adherent cultures during
evaluation for in vitro LRCs. MDA231 cultures or HCT116
spheres were digested into single cells and labeled with the
fluorescent cell tracing dye CFSE, then plated back into
RPMI or Sphere media, respectively. Over the course of 1
week, dividing cells progressively dilute out label and
decrease in fluorescence intensity (Fig. 1A). At 1 week, a
CFSE-intense cell population was distinguishable from non/
low-labeled bulk cells by microscopy under both conditions
(Fig. 1B). When single cells were analyzed by flow cytome-
try, an average CFSE + bright LRC population of 4.2% –
2.1% was detected in HCT116 spheres and 0.99% – 0.14% in
MDA231 adherent cultures (Fig. 1C, representative plots).
Using the mean CFSE intensity to compare cells with the
lowest CFSE intensity (mean CFSE= 26.8) to the highest
CFSE intensity (black box, mean CFSE = 227), HCT116 CFSE
bright cells were *3 cell divisions behind non/low-labeled
bulk cells (Fig. 1C), indicating a distinct population of slowly
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dividing cells. Cell cycle analysis of HCT116 CFSE + spheres
revealed a 2-fold increase in G2/M phase cells when com-
pared with total cells (Fig. 1D), suggesting an extended G2/
M phase or arrest.
We next used CFSE labeling to determine whether slow-
cycling cells were detectable in an in vivo system. HCT116
and MDA231 cells were labeled with CFSE and grafted
subcutaneously or into the mammary fat pads, respectively,
of NOD/SCID mice. After 2 weeks of growth, flow cytom-
etry indicated a population of CFSE + cells distinguish-
able from the bulk tumor cells: HCT116 with 11.6% – 2.9%
and MDA231 with 9.7% – 3.5% CFSE + cells (Fig. 2). To
FIG. 1. In vitro identification of LRCs. (A) Flow cytometry plot demonstrating HCT116 sphere dilution of CFSE over 7 days.
All HCT116 cells are intensely positive directly after labeling. Over time, label is lost in rapidly proliferating cells, with a tail
of more slowly cycling LRCs visible only after 3 days. (B) Florescent and bright-field image overlay of HCT116 sphere
cultures and MDA231 adherent cultures 1 week after labeling (scale bar= 100 mm). CFSE + cells (white arrows) are visible under
a fluorescent microscope. (C) Representative flow cytometry plot of digested HCT116 sphere cultures and MDA231 adherent
cultures after 7 days. Black box depicts the approximate collection gate around the highest CFSE-intense cells. (D) Re-
presentative cell cycle profile of total HCT116 sphere cultures. Total cells (gray) and CFSE + LRCs (black) after 1 week and
adjacent quantification bar graphs. CFSE, carboxyfluorescein diacetate, succinimidyl ester; LRC, label-retaining cell.
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FIG. 2. In vivo identification of LRCs. (A) Composition of CFSE-positive cells after 2 weeks of tumor growth in HCT116
colon tumors, MDA231 breast tumors, and the primary breast sample 2597T tumors. (B) Representative flow cytometry plot
of CFSE cell intensities for HCT116 tumor xenografts after 2 weeks of growth. White peak is the unanalyzed data according to
CFSE intensity and cell number. Gray peaks represent predicted dilution populations calculated by the proliferation wizard of
the Modfit software package. Six separate division peaks were calculated, with two small peaks of greatest CFSE intensity not
visible. Black bar approximates the gate used during live sorting to collect the highest 5% intense cells. (C) Fluorescent staining
of HCT116, MDA231, and 2597T xenograft tumors after 2 weeks of growth. Only rare cells retain a visible intensity of CFSE
(white arrows) while less intense cells are still detectable by flow cytometry (scale bar= 100 mm). (D) Cell cycle profiles for
HCT116 xenografts. CFSE - cells (gray) and CFSE + LRCs (black) after 2 weeks and adjacent quantification bar graphs.
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demonstrate that this was not limited to cell lines, we per-
formed similar in vivo studies with a patient-derived pri-
mary breast tumor (2597T) that demonstrated an LRC
content of 5.3% – 0.8% (Fig. 2A). Using the proliferation
wizard from the Modfit software package, we calculated that
the top 5% CFSE-intense cells have undergone at least 3–5
fewer cell divisions than the bulk tumors cells in HCT116
xenografts (Fig. 2B). On frozen tissue sections of tumor xe-
nografts, only a small number of scattered CFSE + cells were
detectable (Fig. 2C), demonstrating the sensitivity of flow
cytometric analysis over immunofluorescence microscopy
for this system. When analyzed for cell cycle stage, in vivo
CFSE + cell cycle profiles were similar to bulk tumor cells
with only a slight enrichment for the G2/M phase (Fig. 2D).
LRCs are tumorigenic and not senescent
To assess the capacity of LRCs to contribute to tumor
growth, we live sorted pulse-chased HCT116 spheres (Fig.
3A, Row 1) and replated CFSE + cells. After 1 week,*75% of
CFSE + cells had divided to form spheres (Row 2). It is in-
teresting to note that 25% of cells did not appear to divide
and retained high levels of the CFSE label, suggesting that a
population of LRCs may exhibit long-term cell cycle arrests.
FIG. 3. LRCs are colony forming and tumorigenic. (A) HCT116-labeled spheres were digested after 1-week growth (row 1)
and live sorted for CFSE + cells (white arrows). Fluorescent and bright-field imaging of representative HCT116 CFSE + cell
growth after 1-week (row 2). (B) HCT116 or 2597T CFSE-labeled tumors (column 1) were digested into single cells and live
sorted for CFSE + cells (EpCAM + and Lin - ). Hematoxylin and eosin images of CFSE + xenograft growth (column 2). CFSE +
tumors are histologically similar to both parental tumor xenografts, and in the case of 2597T, similar to the primary patient
tumor as well (column 3) (scale bar = 100 mm).
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To determine whether in vivo–derived LRCs are tumori-
genic, pulse-chased HCT116 and 2597T primary tumors were
digested to single cells and live sorted for a maximum of 5%
of the top CFSE + cells. When reinjected into mice, large tu-
mors were formed within 2 months. Histologically, CFSE +
tumors were similar to tumors formed from the established
parental cell line (Fig. 3B). In the primary 2597T breast line,
CFSE + tumors were also similar to the histology of the pri-
mary patient sample.
LRCs are enriched following chemotherapy
Slow-cycling LRCs in adult tissues have been demonstrated
to survive chemotherapy better than other cells within the
tissue [6,13,14]. To investigate whether chemotherapy resis-
tance is also a characteristic of our slow-cycling tumor cells,
we labeled HCT116 cells, and chased for 1 week in sphere
media. Single-cell digests were then either plated in DMSO
vehicle control or a chemotherapy reagent at a combined
concentration to kill between 75% and 90% of cells and discern
more resistant cells (Fig. 4A). After 3 days in culture, DMSO-
treated cells had expanded by 5-fold, while Oxaliplatin- (15%),
5-FU– (2.8%), and FOX-treated (3.3%) cultures expectedly
contained only a fraction of viable cells compared with DMSO
controls (Fig. 4B). When analyzed for CFSE, DMSO control
samples demonstrated an expected decrease in CFSE content
(15.2% to 7.1%) as these cells continued to proliferate. Strik-
ingly, Oxaliplatin-, 5-FU–, and FOX-treated cells demonstrated
3.4-, 6.7-, and 7.1-fold increase in CFSE + cell content, re-
spectively (Fig. 4C). To determine whether LRCs are capable
FIG. 4. In vitro LRCs demonstrate increased therapy resistance. (A) Timeline for in vitro HCT116 chemotherapy treatment
experiments. (B) Number of surviving cells after 3 days in the presence of DMSO, 2 mM Oxaliplatin (Oxali), 250 mM
5-fluorouracil (5-FU), or the combination of Oxali and 5-FU ‘‘FOX.’’ (C) Percent CFSE-positive cells after 3 days in the
presence of drug. Oxali-, 5-FU–, and FOX-treated samples are significantly enriched over DMSO-treated samples (n = 3,
*P = 0.01, **P < 0.0001). (D) Representative BrdU incorporation flow cytometry plots for FOX-treated sphere cultures with
single color controls. DMSO, dimethyl sulfoxide.
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of dividing after treatment, HCT116 FOX-treated cultures
were replated in sphere media containing BrdU. After 3
days, 6.2% of total cells were BrdU +/CFSE + cells, suggest-
ing *10% of CFSE + cells (6.2% of 59.1%) had undergone
DNA replication and reentered the cell cycle during this
early postchemotherapy recovery period (Fig. 4D).
To elucidate whether slow-cycling LRCs are chemoresis-
tant in vivo, CFSE-labeled HCT116 cells were engrafted into
NOD/SCID mice and allowed a 12-day chase before being
placed on a FOX treatment regime (Fig. 5A). At the end of
treatment, FOX-treated tumors were significantly smaller in
size (541mg) compared with DMSO-treated controls
(753mg) (Fig. 5B). When analyzed for CFSE content, DMSO-
treated tumors averaged 5.3% CFSE + cells while FOX-
treated tumors had a statistically significant increase in CFSE+
cells at 8.3% (Fig. 5C). When FOX-treated tumors were pulsed
with BrdU for 4 days, LRCs demonstrated the ability to cycle
at least once over the time period through BrdU incorporation
(Fig. 5D) and a cell fraction within all stages of the cell cycle
via DAPI stain (Fig. 5E). Combined, these data demonstrate
the ability for LRCs to reenter the cell cycle and actively
proliferate shortly after chemotherapy treatment.
Discussion
The use ofCFSE to demonstrate the existence of slow-cycling
LRC populations in cancer is divergent from the dye’s general
use of short-term lineage tracing. The CFSE offers the distinc-
tive ability to isolate and further characterize live, slow-cycling
cells apart from other label-retaining methods, like BrdU, that
require cell permeabilization. Further, CFSE dilution and re-
tention relies on a functional cellular phenotype and is inde-
pendent of protein markers with poorly understood functional
contribution to cell dynamics. We demonstrate the existence of
a CFSE LRC population in two epithelial tumors lines and one
primary patient-derived tumor xenograft. Slow-cycling popu-
lations of cells have been found in the normal colon [15] and
normal breast tissues [16–18], suggesting that this characteristic
maybe carried over from their tissues of origin and serve an
important functional role in tissue longevity.
Importantly, the populations of LRCs that we identified
both in vitro and in vivo are capable of reactivation. While it
is conceivable that a population of cells that enter a senescent
state postlabeling would retain label, the identified LRCs are
capable of division when live sorted and replated in Sphere
media and can regenerate tumors in vivo. Taken together,
these data suggest that CFSE + LRCs are capable of driving
tumor formation and regrowth in a clinical setting.
The observed enrichment of LRCs after chemotherapy re-
quires either the preferential expansion of the LRC pool or a
reduction of the nonlabel-retaining bulk cells. Back calculations
of the in vitro–treated DMSOpopulation suggest an increase in
absolute LRC number from*30,000 to*80,000, due to LRC
proliferation that generates partially labeled daughters. How-
ever, this expansion alone cannot account for the significant
increase in overall LRC composition. In addition, the signifi-
cant difference in survival betweenOxaliplatin-treated samples
and 5-FU/FOX–treated samples further supports the concept
of LRC enrichment due to increased chemotherapy resistance.
Oxaliplatin had insignificant overall kill and only modest LRC
enrichment, while 5-FU killed a majority of cells and demon-
strated a more profound LRC enrichment (Fig. 4). These data
indicate that LRCs are better able to survive standard chemo-
therapy treatments and their enrichment is related to chemo-
therapeutic efficiency of killing nonlabel-retaining bulk cells.
In vivo we see a similar pattern where treatment with
clinically relevant concentrations of FOX resulted in modest
debulking of tumors, corresponding with only modest LRC
enrichment (Fig. 5). Unfortunately, increasing drug concen-
trations or decreasing time between injections proved fatal
for a high percentage of mice and hampered our ability to
determine whether a more profound debulking of tumor
cells would lead to greater fold LRC enrichment.
In in vitro sphere assays, HCT116 LRCs were enriched for
cells in the G2/M phases of the cell cycle (Fig. 1C). Other
groups have associated a G2/M phase arrest with increased
resistance to multiple forms of chemotherapy and a pro-
pensity to evade apoptosis [19,20]. It is likely therefore that
the G2/M arrest observed in our LRCs is a contributing
factor to the observed enrichment, perhaps by extending the
time for repair or providing the means to evade apoptotic
signals. It is also possible that simply arresting in the G2/M
state primes LRCs to better respond to cellular stresses and
apoptotic signaling that results from therapeutic treatment.
While the ability of cancer cells to survive chemotherapy is
important, clinically significant cells must also be capable of
proliferation to stimulate tumor recurrence. Therefore, it is
important to establish that CFSE + LRCs are not avoiding the
cytotoxic effects of FOX treatment by entering a permanently
nondividing state. Both in vitro and in vivo, a subset of FOX-
treated LRCs was able to incorporate BrdU shortly after re-
moval of FOX (Figs. 4D and 5D), demonstrating the capacity
of LRCs to actively proliferate and conceivably contribute to
tumor recurrence after treatment. This suggests that slow-
cycling cells are activated after chemotherapy withdrawal to
repropagate the tumor.
Given the therapy-resistant and tumorigenic properties of
LRCs, it is conceivable to conclude an association between
slow-cycling cells and cancer stem cells (CSCs).
The concept that subsets of tumor cells have increased
capacity for tumor propagation in mice is still evolving. For
instance, in some models of cancer stem cells (such as mel-
anoma), most if not all cells are tumorigenic [21], while in
other system (such as in colon cancer), surface markers have
been shown to be nonspecific, with marker-positive and
negative cells showing tumorigenicity [22,23]. Evidence from
other groups in ovarian tumors, mammary tumors, and
melanoma cell lines has demonstrated a connection between
the slow-cycling phenotype and identified CSC populations
[8,18,24]. However, we believe our findings to be biologically
and clinically significant, independent of a cancer stem cell
model. Given the possibility that most or all cancer cells
could be tumorigenic, we identify a subset of slow-cycling
cells that is better able to survive treatment, and thus more
capable of leading to tumor recurrence.
In summary, we propose a model in which a subset of
slow-cycling tumor cells has enhanced chemoresistance and
proliferate after chemotherapy withdrawal to allow for tumor
recurrence in a clinical setting. Further, this study details an
innovative method to isolate, enrich, and better characterize a
population of live therapy-resistant cells in both in vitro cul-
tures and in vivo xenografts. This work should allow for future
live enrichment and better characterization of chemoresistant
populations to develop more targeted therapies.
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FIG. 5. CFSE LRCs and chemotherapy resistance model. (A) Timeline for in vivo HCT116 xenograft treatment regime. (B)
Tumor masses at the end of treatment for DMSO (n = 12) and FOX (n = 8) (**P < 0.01). (C) CFSE composition for DMSO- and
FOX-treated tumors (*P= 0.045). (D) Representative BrdU incorporation flow cytometry plots for FOX-treated tumors pulsed
with BrdU. CFSE + cells incorporated approximately equal amounts of BrdU as CFSE - . (E) Representative 4¢,6-diamidine-2¢-
phenylindole dihydrochloride (DAPI)-derived cell cycle profiles for FOX-treated tumors pulsed with BrdU with adjacent
quantification bar graphs.
SLOW-CYCLING THERAPY-RESISTANT CANCER CELLS 1829
Acknowledgments
The authors thank the University of Massachusetts
Medical School Cancer Center Tissue and Tumor Bank
(www.umassmed.edu/cancercenter/tissuebank/index.aspx)
for samples and staining.
W.M. Keck Foundation Award and Department of De-
fense (BC074714) (Stephen Lyle); R01-CA119061 ( JeanMarie
Houghton).
Author Disclosure Statement
There are no conflicts of interests in connection with this
manuscript.
References
1. Andre T, C Boni, M Navarro, J Tabernero, T Hickish, C
Topham, A Bonetti, P Clingan, J Bridgewater, F Rivera and
A de Gramont. (2009). Improved overall survival with ox-
aliplatin, fluorouracil, and leucovorin as adjuvant treatment
in stage II or III colon cancer in the MOSAIC trial. J Clin
Oncol 27:3109–3116.
2. Brewster AM, GN Hortobagyi, KR Broglio, SW Kau, CA
Santa-Maria, B Arun, AU Buzdar, DJ Booser, V Valero, M
Bondy and FJ Esteva. (2008). Residual risk of breast cancer
recurrence 5 years after adjuvant therapy. J Natl Cancer Inst
100:1179–1183.
3. Bao S, Q Wu, RE McLendon, Y Hao, Q Shi, AB Hjelmeland,
MW Dewhirst, DD Bigner and JN Rich. (2006). Glioma stem
cells promote radioresistance by preferential activation of
the DNA damage response. Nature 444:756–760.
4. Jung Y and SJ Lippard. (2007). Direct cellular responses to
platinum-induced DNA damage. Chem Rev 107:1387–1407.
5. Papamichael D. (1999). The use of thymidylate synthase
inhibitors in the treatment of advanced colorectal cancer:
current status. Oncologist 4:478–487.
6. Selleri S, F Arnaboldi, M Palazzo, U Hussein, A Balsari and
C Rumio. (2005). Caveolin-1 is expressed on multipotent
cells of hair follicles and might be involved in their resistance
to chemotherapy. Br J Dermatol 153:506–513.
7. Morshead CM, BA Reynolds, CG Craig, MW McBurney,
WA Staines, D Morassutti, S Weiss and D van der Kooy.
(1994). Neural stem cells in the adult mammalian forebrain:
a relatively quiescent subpopulation of subependymal cells.
Neuron 13:1071–1082.
8. Roesch A, M Fukunaga-Kalabis, EC Schmidt, SE Zabier-
owski, PA Brafford, A Vultur, D Basu, P Gimotty, T Vogt
and M Herlyn. (2010). A temporarily distinct subpopulation
of slow-cycling melanoma cells is required for continuous
tumor growth. Cell 141:583–594.
9. Kusumbe AP and SA Bapat. (2009). Cancer stem cells and an-
euploid populations within developing tumors are the major
determinants of tumor dormancy. Cancer Res 69:9245–9253.
10. Dembinski JL and S Krauss. (2009). Characterization and
functional analysis of a slow cycling stem cell-like subpop-
ulation in pancreas adenocarcinoma. Clin Exp Metastasis
26:611–623.
11. Fillmore CM and C Kuperwasser. (2008). Human breast
cancer cell lines contain stem-like cells that self-renew, give
rise to phenotypically diverse progeny and survive chemo-
therapy. Breast Cancer Res 10:R25.
12. Grimshaw MJ, L Cooper, K Papazisis, JA Coleman, HR
Bohnenkamp, L Chiapero-Stanke, J Taylor-Papadimitriou
and JM Burchell. (2008). Mammosphere culture of metastatic
breast cancer cells enriches for tumorigenic breast cancer
cells. Breast Cancer Res 10:R52.
13. Cheng T, N Rodrigues, H Shen, Y Yang, D Dombkowski, M
Sykes and DT Scadden. (2000). Hematopoietic stem cell qui-
escence maintained by p21cip1/waf1. Science 287:1804–1808.
14. Dekaney CM, AS Gulati, AP Garrison, MA Helmrath and SJ
Henning. (2009). Regeneration of intestinal stem/progenitor
cells following doxorubicin treatment of mice. Am J Physiol
Gastrointest Liver Physiol 297:G461–G470.
15. Potten CS. (1998). Stem cells in gastrointestinal epithelium:
numbers, characteristics and death. Philos Trans R Soc Lond
B Biol Sci 353:821–830.
16. Welm BE, SB Tepera, T Venezia, TA Graubert, JM Rosen and
MA Goodell. (2002). Sca-1(pos) cells in the mouse mammary
gland represent an enriched progenitor cell population. Dev
Biol 245:42–56.
17. Shackleton M, F Vaillant, KJ Simpson, J Stingl, GK Smyth,
ML Asselin-Labat, L Wu, GJ Lindeman and JE Visvader.
(2006). Generation of a functional mammary gland from a
single stem cell. Nature 439:84–88.
18. Pece S, D Tosoni, S Confalonieri, G Mazzarol, M Vecchi, S
Ronzoni, L Bernard,GViale, PGPelicci and PPDi Fiore. (2010).
Biological and molecular heterogeneity of breast cancers cor-
relates with their cancer stem cell content. Cell 140:62–73.
19. Chikamatsu K, H Ishii, G Takahashi, A Okamoto, M Mor-
iyama, K Sakakura and K Masuyama. (2011). Resistance to
apoptosis-inducing stimuli in CD44 + head and neck squa-
mous cell carcinoma cells. Head Neck [Epub ahead of print];
DOI: 10.1002/hed.21732.
20. Harper LJ, DE Costea, L Gammon, B Fazil, A Biddle and IC
Mackenzie. (2010). Normal and malignant epithelial cells
with stem-like properties have an extended G2 cell cycle
phase that is associated with apoptotic resistance. BMC
Cancer 10:166.
21. Quintana E, M Shackleton, MS Sabel, DR Fullen, TM John-
son and SJ Morrison. (2008). Efficient tumour formation by
single human melanoma cells. Nature 456:593–598.
22. Shmelkov SV, JM Butler, AT Hooper, A Hormigo, J Kushner,
T Milde, R St Clair, M Baljevic, I White, et al. (2008). CD133
expression is not restricted to stem cells, and both CD133 +
and CD133- metastatic colon cancer cells initiate tumors.
J Clin Invest 118:2111–2120.
23. Ricci-Vitiani L, DG Lombardi, E Pilozzi, M Biffoni, M To-
daro, C Peschle and R De Maria. (2007). Identification and
expansion of human colon-cancer-initiating cells. Nature
445:111–115.
24. Gao MQ, YP Choi, S Kang, JH Youn and NH Cho. (2010).
CD24 + cells from hierarchically organized ovarian cancer
are enriched in cancer stem cells. Oncogene 29:2672–2680.
Address correspondence to:
Dr. Stephen Lyle
Department of Cancer Biology
University of Massachusetts Medical School
Worcester, MA 01605
E-mail: stephen.lyle@umassmed.edu
Received for publication August 22, 2011
Accepted after revision October 4, 2011
Prepublished on Liebert Instant Online October 5, 2011
1830 MOORE, HOUGHTON, AND LYLE
